{"entity":{"id":"nct06980272","kind":"trial","name":"SSGJ-707 in Advanced Non-Small Cell Lung Cancer","aka":[],"tldr":"A phase 3 trial testing PF-08634404 in non-small-cell lung cancer, now recruiting.","summary":"SSGJ-707 in Advanced Non-Small Cell Lung Cancer is a phase 3 interventional study registered as NCT06980272, led by Shenyang Sunshine Pharmaceutical, and recruiting on the registry. Official title: A Randomised Controlled, Multi-centre Phase III Clinical Trial of SSGJ-707 Versus Pembrolizumab as First-line Treatment for PD-L1-Positive Locally-Advanced or Metastatic Non-Small Cell Lung Cancer. Planned enrolment is 420 participants (estimated). The study started in 2025-06-20 and primary completion is expected in 2026-07-30. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT06980272","url":"https://clinicaltrials.gov/study/NCT06980272"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["pf-08634404"],"companies":["3sbio"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06980272","phase":"3","setting":"A Randomized Controlled, Multi-center Phase III Clinical Trial of SSGJ-707 Versus Pembrolizumab as First-line Treatment for PD-L1-Positive Locally-Advanced or Metastatic Non-Small Cell Lung Cancer","sponsor":"Shenyang Sunshine Pharmaceutical","started":"2025-06-20","startedType":"actual","enrolled":420,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06980272/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"pf-08634404","kind":"drug","name":"PF-08634404","route":"/drugs/pf-08634404/"}],"company":[{"id":"3sbio","kind":"company","name":"3SBio","route":"/companies/3sbio/"}]}}